The AI system allows for the quantitative characterisation of solid lung nodules and enables clinicians to analyse morphological data across single or multiple thoracic studies. Credit: Shutterstock / New Africa.

India-based AI firm Qure.ai has announced US Food and Drug Administration (FDA) clearance of its computed tomography (CT) imaging solution designed to help radiologists and pulmonologists examine lung nodules for signs of cancer.

The FDA has granted 510(k) clearance to the company’s AI-powered chest CT solution known as qCT LN Quant.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Qure.ai claims that qCT Quant can analyse individual lung nodules on non-contrast chest CT scans and track volumetric growth as part of progression monitoring in a bid to drive the early detection of cancer.

The AI system allows for the quantitative characterisation of solid lung nodules and enables clinicians to analyse morphological data across single or multiple thoracic studies. At the same time, it generates detailed 2D and 3D reconstructions of nodules and can provide decision-making suggestions for clinicians.

The software comes as part of an add-on to what the company calls the Qure.ai US AI-powered Lung Cancer care continuum, which has already seen use in several international health systems, including the UK’s National Health Service (NHS).

Bhargava Reddy, chief business officer of oncology at Qure.ai said: “This FDA clearance marks a significant milestone for Qure.ai’s mission to enhance lung cancer care in the United States. Already, we’re starting to see the power of AI for incidental pulmonary nodule detection using chest X-ray, across multiple care settings, to boost lung surveillance, especially in states with low lung cancer screening CT uptakes.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“Now, we have the next stage solution in the AI-optimised patient pathway, to evaluate lung nodules on at-risk patient CT scans, giving precise quantitative characterisation, plus tracking volumetric growth over time.”

The announcement follows shortly after the company was able to obtain Health Canada’s Class III medical device licence for its suite of AI solutions. Elsewhere in the AI-powered imaging market, competitor Avicenna.AI has secured Medical Device Regulation (MDR) certification for five of its AI algorithms used to screen for a host of conditions.